The research analyzes 500 S & P companies, comparing spending patterns between the largest firm sand the broader market, with data from 1H 2024 and forecasts for 2025.

As one of the world's biopharmaceutical giants, AstraZeneca has a number of core businesses with unique corporate advantages that will enable it to develop over time.

In 2019, the company had assets of $390.4 billion, net operating income of $28.6 billion. In recent years, the company's net revenue CAGR has been 6.3%, while net profit has fluctuated throughout.